Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients

This publication has 26 references indexed in Scilit:

• Quantitative Determination of Factors Contributing to Doxorubicin Resistance in Multidrug-Resistant Cells
  JNCI: Journal of the National Cancer Institute, 1989
• Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
  Journal of Clinical Oncology, 1989
• Acute hemodynamic and antiischemic properties of intravenous bepridil in coronary artery disease
  The American Journal of Cardiology, 1989
• Induction by verapamil of a rapid increase in ATP consumption in multidrug‐resistant tumor cells
  The FASEB Journal, 1988
• Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and-sensitive cell lines
  Cancer Chemotherapy and Pharmacology, 1987
• Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: Role of protein binding
  Cancer Letters, 1987
• Improved method for the determination of 4′-epidoxorubicin and seven metabolites in plasma by high-performance liquid chromatography
  Journal of Chromatography B: Biomedical Sciences and Applications, 1987
• Verapamil Reversal of Clinical Doxorubicin Resistance in Human Cancer A Wilshire Oncology Medical Group Pilot Phase I-II Study
  American Journal of Clinical Oncology, 1986
• Pharmacokinetics and metabolism of bepridil
  The American Journal of Cardiology, 1985
• Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell Lines
  Science, 1983